A 52-Week,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.

Trial Profile

A 52-Week,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Amilomotide (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
    • 11 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov [parent trial: NCT00733863].
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top